Article info

Download PDFPDF

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

Authors

  1. Correspondence to Dr Roy M Fleischmann, Medicine, University of Texas Southwestern, Dallas, TX 75390, USA; rfleischmann{at}arthdocs.com
View Full Text

Citation

Fleischmann RM, Genovese MC, Enejosa JV, et al
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

Publication history

  • Received May 22, 2019
  • Revised July 13, 2019
  • Accepted July 15, 2019
  • First published July 30, 2019.
Online issue publication 
October 15, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.